Elizabeth M. Holland

I'll research this attorney before writing the summary.

Summary — Elizabeth M. Holland (as tracked) / Goodwin Procter

Specialty and focus areas. The single tracked appearance is Regeneron Pharmaceuticals, Inc. v. Samsung Bioepis Co., Ltd. (N.D. W. Va.), a BPCIA biosimilar action over Regeneron's aflibercept (EYLEA) franchise. That places the practice squarely in life-sciences/biologics patent litigation — BPCIA and, by extension, Hatch-Waxman-type pharmaceutical disputes — rather than the Wi-Fi/standards, software, or mechanical arts. The aflibercept case was consolidated into the multi-district litigation in the Northern District of West Virginia alongside parallel Regeneron actions against Amgen, Mylan/Biocon, Celltrion, Formycon, and Sandoz.

Side preference. The tracked record shows one plaintiff-side appearance and zero defendant-side appearances. In the tracked matter she appears for the patent owner/innovator as plaintiff. There is no indication of an NPE/PAE prosecution practice. Publicly available practice descriptions for the best-documented attorney under this name frame the practice as representing innovator/life-sciences clients, although a 2014 Goodwin Procter lateral-hire announcement noted earlier Hatch-Waxman experience on behalf of both branded and generic drug companies.

Firm context and a naming caveat. The case list places her at Goodwin Procter as Counsel. I could not independently verify a current Goodwin Procter practice page or bio for a counsel-level attorney named "Elizabeth M. Holland," so the following should be treated as a probable (not confirmed) identification: the prominent Goodwin Procter IP litigator under this name is Elizabeth J. Holland, a partner in the firm's IP Litigation group from 2014 (joining from Kenyon & Kenyon) until February 2022, when she led a five-partner life-sciences IP team to Allen & Overy (now A&O Shearman), where she is Global Co-Head of IP Litigation. Because that departure predates the 2023 filing of the Regeneron v. Samsung Bioepis case, the "Elizabeth M. Holland" recorded at Goodwin on that matter is either a different, less senior Goodwin attorney or a middle-initial/data discrepancy in the source. I did not find a Goodwin counsel bio for her, and the two identities should not be merged without confirmation.

Notable outcomes, PTAB, and bar. In the tracked aflibercept litigation, Regeneron obtained a preliminary injunction against Samsung Bioepis, and the Federal Circuit affirmed preliminary injunctions against Celltrion, Samsung, and Formycon on U.S. Patent No. 11,084,865; the PTAB then denied institution of Samsung's IPR2025-00176 (and Formycon's IPR2025-00233) under § 314(a)/Fintiv, citing the advanced MDL proceedings. Regeneron and Samsung filed a joint stipulation in February 2026 to dismiss all claims and vacate the injunction, with Samsung permitted to launch its aflibercept biosimilar in January 2027. Attribution of specific briefing or argument to this attorney individually is not verifiable from the sources reviewed. If the identification with Elizabeth J. Holland is correct, she has substantial PTAB experience as lead counsel in IPRs (e.g., for Celltrion, Fresenius Kabi, Teva, and Regeneron/Novartis) and appears on PTAB powers of attorney under USPTO Registration No. 47,657; she has argued Federal Circuit appeals. No education information was reliably sourced, and no bar admissions beyond the USPTO registration could be confirmed.